Panion & Bf Biotech Valuation

Q: What is the Fair Price of 1760 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

1760 (NT$91) is trading above our estimate of [[fair value]] (NT$15.66)

Is 1760 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1760 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1760 (NT$91) is trading above our estimate of fair value (NT$15.66)

Significantly Below Fair Value: 1760 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1760?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 1760. This is calculated by dividing 1760's market cap by their current preferred multiple.
What is 1760's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	NT$7.48b

1760 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.8x
Enterprise Value/EBITDA	22.8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 1760's PE Ratio compare to its peers?

The above table shows the PE ratio for 1760 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	34.6x
3716 Cenra	15.8x	n/a	NT$5.6b
4119 SCI Pharmtech	77.3x	n/a	NT$10.7b
1734 Sinphar PharmaceuticalLtd	15.4x	n/a	NT$5.6b
4120 Orient EuroPharma	29.7x	n/a	NT$4.3b
1760 Panion & Bf Biotech	77x	n/a	NT$7.5b

Price-To-Earnings vs Peers: 1760 is expensive based on its Price-To-Earnings Ratio (77x) compared to the peer average (34.6x).

Price to Earnings Ratio vs Industry

How does 1760's PE Ratio compare vs other companies in the TW Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	48.0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	48.0%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 1760 is expensive based on its Price-To-Earnings Ratio (77x) compared to the TW Pharmaceuticals industry average (26.4x).

Price to Earnings Ratio vs Fair Ratio

What is 1760's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1760 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	77x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1760's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is less than 20% higher than the current share price.